currency discussion- Top Featured snippets

21st century business herald reporter learned exclusively from insiders that this week, the personal pension expansion policy will be announced, "the time may be December 12th". It is reported that the investable products included in personal pension may include over-the-counter products tracking nearly 20 broad-based indexes such as Shanghai and Shenzhen 300 Index, CSI 500 Index, CSI 800 Index, GEM Index and Kechuang 50 Index.The previous wave of adjustment of the Hang Seng Index was to step back on the long-term trend line at the daily level, which gained support and rebounded recently. Today, it closed above the offensive line, and the long-term trend at the daily level remains intact. On the monthly level, it fell below the offensive line last month, but it is above the offensive line at present, and it closed above 19,738 points this month. The problem is not big, and the long-term trend remains intact, and there is a basis for further strength.

The latest news of personal pension fund, incremental funds are coming!Federal Reserve's December Outlook21st century business herald reporter learned exclusively from insiders that this week, the personal pension expansion policy will be announced, "the time may be December 12th". It is reported that the investable products included in personal pension may include over-the-counter products tracking nearly 20 broad-based indexes such as Shanghai and Shenzhen 300 Index, CSI 500 Index, CSI 800 Index, GEM Index and Kechuang 50 Index.

Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.The latest progress of stamp duty in Hong Kong has come!Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.